Ghrelin Peptide Protects Kidneys from Chemo Damage by Activating SIRT1
Background
Doxorubicin is a potent chemotherapy drug widely used in cancer treatment, but its efficacy is often limited by severe side effects, including doxorubicin-induced nephropathy (kidney damage). This damage is characterized by oxidative stress, inflammation, and cellular apoptosis in renal tissues. Understanding and developing strategies to mitigate doxorubicin's nephrotoxicity is crucial for improving patient outcomes and expanding the therapeutic window of this vital drug.
Results
The study demonstrated that acylated ghrelin significantly attenuated kidney damage induced by doxorubicin. Doxorubicin-treated rats exhibited a 3-fold increase in serum creatinine and BUN levels compared to controls, which was remarkably reduced by acylated ghrelin treatment by 55% and 48%, respectively (p<0.01). > The most significant finding was that acylated ghrelin treatment led to a 2.5-fold increase in SIRT1 (silent information regulator 1) expression and activity in kidney tissues, alongside a 70% reduction in oxidative stress markers like malondialdehyde (p<0.001). Furthermore, inflammatory cytokines such as TNF-α and IL-6 were decreased by 60% and 58% (p<0.05) in ghrelin-treated groups, indicating a strong anti-inflammatory effect. Histopathological analysis confirmed a 75% reduction in tubular damage and glomerular sclerosis, demonstrating substantial structural protection.
Why It Matters
This research highlights acylated ghrelin's potential as a potent renoprotective agent against chemotherapy-induced kidney damage. By activating SIRT1, a protein involved in cellular health and longevity, ghrelin appears to effectively combat oxidative stress and inflammation, which are key drivers of nephropathy. These findings suggest a novel therapeutic strategy that could significantly improve the safety profile of doxorubicin and potentially other nephrotoxic drugs, paving the way for future human clinical trials. Further studies are warranted to confirm these effects in larger animal models and eventually in Phase I/II human trials to assess safety and efficacy.